Annovis Bio, Inc.

Recent News

  • Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study

    Berwyn, Pennsylvania--(Newsfile Corp. - July 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that the Data Safety Monitoring Board (DSMB) has reviewed the safety and tolerability data for Cohort 2 of the Company's Phase 2...

    2021-07-20 8:30 AM EDT
  • Annovis Bio to Present Data at Alzheimer's Association International Conference 2021 Highlighting Positive Clinical Outcomes from Its Two Phase 2a Trials

    Berwyn, Pennsylvania--(Newsfile Corp. - July 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that its abstract has been accepted at the Alzheimer's Association International Conference (AAIC), which will be held online and in-person July 26-30,...

    2021-07-02 8:30 AM EDT
  • Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO

    Berwyn, Pennsylvania--(Newsfile Corp. - July 1, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company that addresses Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced its CEO, Maria L. Maccecchini, Ph.D., was named the winner of the 2021 PACT Enterprise Award for Life Sciences and Healthcare...

    2021-07-01 8:30 AM EDT
  • Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards

    Berwyn, Pennsylvania--(Newsfile Corp. - June 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria L. Maccecchini, Ph.D., was selected as a Life Sciences and Healthcare CEO finalist in the 2021 PACT Enterprise Awards. Hosted by the Philadelphia Alliance for Capital and Technologies (PACT), whose vision is to be the go-to resource for fast growing companies...

    2021-06-24 8:01 AM EDT
  • Annovis Bio to Present at 2021 BIO Digital

    Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its participation in 2021 BIO Digital, the premier biotech event, taking place online June 10-11 & 14-18, 2021.A corporate presentation by Maria L. Maccecchini, Ph.D., CEO of Annovis Bio, will be available to registered attendees beginning at 9:00 a.m. ET on June 10.Attendees at...

    2021-06-10 8:30 AM EDT
  • Annovis Bio Expands Potential Application of ANVS401 to Infectious Diseases with New Preclinical Study

    Berwyn, Pennsylvania--(Newsfile Corp. - June 8, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced preliminary data demonstrating ANVS401, the Company's lead drug candidate, protects certain nerve cells from dying after being infected by gingipains, the virulence factors of Porphyromonas gingivalis (P. gingivalis), which have been identified as pathogenic effectors in AD."We initiated this study last year after...

    2021-06-08 8:30 AM EDT
  • Annovis Bio to Present at Jefferies Virtual Healthcare Conference 2021

    Berwyn, Pennsylvania--(Newsfile Corp. - June 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. Maccecchini will present at the Jefferies Virtual Healthcare Conference 2021 as follows:Date: Friday, June 4, 2021Time: 8:00 a.m. ETWebcast: https://wsw.com/webcast/jeff174/anvs/1866024The presentation will be webcast live and archived for 30 days thereafter.About Annovis Bio Inc.Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is...

    2021-06-03 8:30 AM EDT
  • Annovis Bio's ANVS401 Improves Speed and Accuracy in Alzheimer's and in Parkinson's Patients

    Berwyn, Pennsylvania--(Newsfile Corp. - June 1, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the notable finding that in a test that measures speed, AD and PD patients both respond with a statistically significant increase in correctly coded fields after 25 days of treatment with ANVS401. The test was part of the Company's ongoing Phase 2a study in AD and PD patients."Our hypothesis...

    2021-06-01 8:30 AM EDT